Neuromyelitis optica spectrum disorder (NMOSD) attacks the optic nerve, spinal cord and brain stem, often leading to irreversible blindness and paralysis—and in the most severe cases—this can occur with just one attack. Patients may also experience loss of sensation, bladder and bowel dysfunction, nerve pain and respiratory failure, with each subsequent attack leading to further damage and disability. As of 2016, there were approximately 10,000 people in the U.S. suffering from NMOSD (Flanagan EP. Ann Neurol. 2016;79(5):775-783).
Viela recently announced the U.S. FDA approval of UPLIZNA® (inebilizumab-cdon) for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquarporin-4 (AQP4) antibody positive. Learn more about UPLIZNA® by visiting the product website: